Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.
about
Guidelines for the management of myeloproliferative neoplasmsPolycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617FNew Therapeutic Approaches in Polycythemia VeraJanus kinase inhibitors: jackpot or potluck?Management of polycythaemia vera: a critical review of current data.Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinibA phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.Ruxolitinib: A Review in Polycythaemia Vera.Polycythemia Vera Management and Challenges in the Community Health Setting.Pharmacological management of essential thrombocythemia.The European LeukemiaNet: achievements and perspectives.Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia.Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.Emerging treatments for essential thrombocythemiaDecrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.Philadelphia-negative chronic myeloproliferative neoplasmsImpaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy.Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patientsAllogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemiaPatterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart reviewJAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.Update on JAK2 Inhibitors in Myeloproliferative NeoplasmJAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy[Blood count results from hypertensive patients seen in laboratory of CHU-HJRB Antananarivo in 2013].Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia veraNovel and emerging therapies for the treatment of polycythemia veraMolecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2aPhiladelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.JAK2 inhibitors: what's the true therapeutic potential?Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.New JAK2 inhibitors for myeloproliferative neoplasms.JAK2 inhibitors: are they the solution?
P2860
Q26778326-72A0D57A-5C59-4C51-A05B-65C18A7788CBQ26795666-29043666-05CA-41EF-9BE3-40DCE0B7BA17Q26795677-9E447898-3CFC-4840-8939-310D252FEB31Q27027230-68E4E011-950A-488A-8C63-701E3EFB334EQ31009757-B566ADB7-FECA-4F6B-BCAC-D12AC4F7E79BQ33402522-A05BE82F-7F71-4E75-A638-ECC4A01904BBQ33411637-2DF637C5-63AC-43F7-A631-5714E2F2BD6EQ33425781-A567D32F-07D8-4603-B07F-8E9BEC5E4F11Q33803036-2DD99135-28CB-4FDE-B90C-9002B8AF0E36Q34344384-FB8DE712-96D9-4CC6-B462-F0AA830AF695Q34451619-C4F8DF69-39C2-477D-81FA-8E2FBCE65396Q34516397-473B7920-D93A-4149-8EAF-33DE2687E67FQ35188877-74BCE7D0-EBA5-4D55-B0C6-FDF7DAA23A11Q35433259-AE6776A6-9781-4262-9752-8C0C324C7510Q35683853-107119A8-6A36-40AB-B6F6-F57372D11ED7Q35944657-1B82A18C-2F43-499F-9A0C-729156A88DF7Q35987564-6F7890A4-D979-4EFE-916F-BD8F7133FA85Q36169641-BC7261B0-DB40-4B96-A461-57CC18988BDAQ36169783-4256AE57-2A79-4002-B795-A5FB180A0B36Q36283143-E38BB044-F271-42E3-BC14-37879CBA03A1Q36303858-52F75822-E938-42F1-9123-2790EA901347Q36311347-DE52DC55-95CE-4C68-B5F6-7F1572EC7EC6Q36366962-B3C73B4A-267D-4700-9939-F3D083243C1BQ36404698-5B5B673D-1B13-488C-8816-5FD208F9B4B4Q36529881-631D48CD-3508-41AE-B290-FA4F9E3610F9Q36612537-C3872D45-77B4-4037-92A6-5D7282B1CF89Q36612569-26F71899-0974-45DB-9CEA-2BDA0CB8F3C0Q36765086-0BC714FC-7898-44A9-AA9D-24FC90FE049DQ36888749-F93401EE-14E6-4153-8B76-9B681EC2E950Q36907860-3E8C366E-AECB-4299-BFC0-691FE52C9965Q36938773-6C8FDA35-8CE5-495E-8706-C8035B2362FCQ37069633-DC616FA2-F92B-4A08-87A5-180FF858FE61Q37083947-D0AC91CF-3E9A-4930-9800-560F427BE1F9Q37163590-B4802D77-3DCC-4F7B-93C2-6C6911B0661FQ37275858-8599F2E0-508E-40CC-93CB-8940D11B5481Q37676280-E5AD4DBC-243C-4258-807B-098125B3F48EQ37811430-0FADF011-18B5-4594-9E58-3C15B87BD6B1Q37833893-9A233E85-F8AC-4488-9403-15E631596BF7Q37869152-363F3FFD-F256-4D24-9380-C4E6266B1786Q37950581-985DE1B9-0F88-46AC-ADEA-DC84ACDDEEE6
P2860
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Response criteria for essentia ...... kemiaNet consensus conference.
@en
Response criteria for essentia ...... kemiaNet consensus conference.
@nl
type
label
Response criteria for essentia ...... kemiaNet consensus conference.
@en
Response criteria for essentia ...... kemiaNet consensus conference.
@nl
prefLabel
Response criteria for essentia ...... kemiaNet consensus conference.
@en
Response criteria for essentia ...... kemiaNet consensus conference.
@nl
P2093
P50
P1433
P1476
Response criteria for essentia ...... ukemiaNet consensus conference
@en
P2093
Alessandro M Vannucchi
Claire Harrison
Eva Lengfelder
Giovanni Barosi
Guido Finazzi
Gunnar Birgegard
John T Reilly
Martin Griesshammer
Mary Frances McMullin
Tiziano Barbui
P304
P356
10.1182/BLOOD-2008-09-176818
P407
P577
2009-03-10T00:00:00Z